June 26 P&P Quick Takes: FDA solicits comments on transparency programs; plus Louisiana’s HCV drug model and more

FDA seeking feedback on clinical data pilot
FDA is seeking feedback on two programs designed to improve clarity and transparency related to drug approval decisions. Under the Clinical Data Summary Report pilot, launched in January 2018, FDA will disclose portions

Read the full 395 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE